Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015

Description: Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015

Summary

The report ‘Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015’, provides an overview of the Bipolar Disorder (Manic Depression)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bipolar Disorder (Manic Depression) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bipolar Disorder (Manic Depression) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bipolar Disorder (Manic Depression) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bipolar Disorder (Manic Depression)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction

REPORT COVERAGE

Bipolar Disorder (Manic Depression) Overview
Therapeutics Development
Pipeline Products for Bipolar Disorder (Manic Depression) - Overview
Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis
Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies
Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes
Bipolar Disorder (Manic Depression) - Pipeline Products Glance

Late Stage Products
Clinical Stage Products
Early Stage Products

Bipolar Disorder (Manic Depression) - Products under Development by Companies
Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes
Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development

Aequus Pharmaceuticals Inc.
ANP Technologies, Inc.
AstraZeneca Plc
Convergence Pharmaceuticals Ltd.
D-Pharm Ltd.
Delpor, Inc.
Intas Pharmaceuticals Ltd.
Intra-Cellular Therapies, Inc.
Johnson & Johnson
KemPharm, Inc.
Neurocrine Biosciences, Inc.
Omeros Corporation
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Reviva Pharmaceuticals Inc.
SK Biopharmaceuticals Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Teva Pharmaceutical Industries Limited
Zogenix, Inc.
Zysis Limited

Bipolar Disorder (Manic Depression) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles
ANP-010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

aripiprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress

aripiprazole CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress

aripiprazole ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CNV-1061436 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DP-VPA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Bipolar Disorder - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Cancer and Neurodegenerative Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ebselen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Endoxifen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ITI-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-18038683 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KP-303 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lurasidone hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NP-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
paliperidone palmitate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PGW-5 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
quetiapine fumarate ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
risperidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
risperidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RP-5063 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SKL-PSY - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Bipolar Disorder - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit VMAT-2 for Schizophrenia, Bipolar Disorder and Movement Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target GPR50 for CNS and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YKP-3089 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ziprasidone mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bipolar Disorder (Manic Depression) - Recent Pipeline Updates
Bipolar Disorder (Manic Depression) - Dormant Projects
Bipolar Disorder (Manic Depression) - Discontinued Products
Bipolar Disorder (Manic Depression) - Product Development Milestones
Featured News & Press Releases
Nov 16, 2015: Aequus Receives Approval from Health Canada to Initiate Phase 1 Clinical Trial of Aripiprazole Transdermal Patch
Jul 22, 2015: Intra-Cellular Therapies Announces Phase 3 Clinical Development Program for the Treatment of Depressive Episodes Associated With Bipolar Disorder
May 28, 2015: Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole
Mar 30, 2015: Sunovion Pharmaceuticals Europe to Present New Data on LATUDA (lurasidone) at the 23rd European Congress of Psychiatry
Jan 14, 2015: Sunovion Pharmaceuticals Files Patent Infringement Lawsuits Regarding Latuda
Jan 13, 2015: Germany's Federal Court Invalidates AstraZeneca's Patent on Seroquel XR
Apr 30, 2014: Otsuka announces 2014 first quarter U.S. net sales figures of ABILIFY
Apr 03, 2014: Dainippon Sumitomo Pharma Announces Health Canada Approval of LATUDA (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Patients with Bipolar Depression
Appendix
Methodology
Coverage
Number of Products under Development for Bipolar Disorder (Manic Depression), H2 2015

Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2015

Bipolar Disorder (Manic Depression) - Pipeline by Aequus Pharmaceuticals Inc., H2 2015

Bipolar Disorder (Manic Depression) - Pipeline by ANP Technologies, Inc., H2 2015

Bipolar Disorder (Manic Depression) - Pipeline by AstraZeneca Plc, H2 2015

Bipolar Disorder (Manic Depression) - Pipeline by Convergence Pharmaceuticals Ltd., H2 2015

Bipolar Disorder (Manic Depression) - Pipeline by D-Pharm Ltd., H2 2015

Bipolar Disorder (Manic Depression) - Pipeline by Delpor, Inc., H2 2015

Bipolar Disorder (Manic Depression) - Pipeline by Intas Pharmaceuticals Ltd., H2 2015

Bipolar Disorder (Manic Depression) - Pipeline by Intra-Cellular Therapies, Inc., H2 2015

Bipolar Disorder (Manic Depression) - Pipeline by Johnson & Johnson, H2 2015

Bipolar Disorder (Manic Depression) - Pipeline by KemPharm, Inc., H2 2015

Bipolar Disorder (Manic Depression) - Pipeline by Neurocrine Biosciences, Inc., H2 2015

Bipolar Disorder (Manic Depression) - Pipeline by Omeros Corporation, H2 2015

Bipolar Disorder (Manic Depression) - Pipeline by Otsuka Holdings Co., Ltd., H2 2015

Bipolar Disorder (Manic Depression) - Pipeline by Pfizer Inc., H2 2015

Bipolar Disorder (Manic Depression) - Pipeline by Reviva Pharmaceuticals Inc., H2 2015
RESEARCH AND MARKETS

Bipolar Disorder (Manic Depression) - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015
Bipolar Disorder (Manic Depression) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Bipolar Disorder (Manic Depression) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Bipolar Disorder (Manic Depression) - Pipeline by Zogenix, Inc., H2 2015
Bipolar Disorder (Manic Depression) - Pipeline by Zysis Limited, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015

Bipolar Disorder (Manic Depression) Therapeutics - Recent Pipeline Updates, H2 2015
Bipolar Disorder (Manic Depression) - Dormant Projects, H2 2015
Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..1), H2 2015
Bipolar Disorder (Manic Depression) - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Bipolar Disorder (Manic Depression), H2 2015
Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015
Ordering: 

Order Online - http://www.researchandmarkets.com/reports/3608142/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015
Web Address: http://www.researchandmarkets.com/reports/3608142/
Office Code: SCH3FX9H

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  Mrs  Dr  Miss  Ms  Prof
First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: _______________________________________________________________
City: _________________________________________________________________
Postal / Zip Code: ______________________________________________________
Country: ______________________________________________________________
Phone Number: __________________________________________________________
Fax Number: ____________________________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World